Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleArticle

Preclinical Evaluation of Anti-inflammatory Activities of the Novel Pyrrolopyrimidine PNU-142731A, a Potential Treatment for Asthma

Jia En Chin, Cheryl A. Hatfield, Greg E. Winterrowd, Raymond F. Krzesicki, Kathy L. Shull, Stephen F. Fidler, Karen P. Kolbasa, John R. Brashler, Robert L. Griffin, William E. Fleming, James M. Justen, Lee S. Banitt, Gordon L. Bundy and Ivan M. Richards
Journal of Pharmacology and Experimental Therapeutics July 1999, 290 (1) 188-195;
Jia En Chin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cheryl A. Hatfield
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Greg E. Winterrowd
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raymond F. Krzesicki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathy L. Shull
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen F. Fidler
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karen P. Kolbasa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John R. Brashler
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert L. Griffin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William E. Fleming
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James M. Justen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lee S. Banitt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gordon L. Bundy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ivan M. Richards
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The anti-inflammatory properties of a novel pyrrolopyrimidine, PNU-142731A, in a murine model of antigen-induced eosinophilic lung inflammation are described. PNU-142731A, when given orally, demonstrated a dose-related inhibition of eosinophil- and lymphocyte-rich accumulation in the airways of ovalbumin (OA)-sensitized and challenged (OA/OA) C57BL/6 mice. The magnitude of the suppression of lung inflammation was also dependent on length of treatment. Reductions in the levels of interleukin (IL)-5, IL-6, and IgA in the bronchoalveolar lavage fluid of treated OA/OA mice, when compared with vehicle-sensitized control mice (V/OA), were observed. Plasma concentrations of IL-5, total IgE, and OA-specific IgG1 were also lowered in OA/OA mice by treatment. Histological assessment of formalin-fixed lung tissue sections confirmed that the compound blocked the accumulation of eosinophils in the airway tissue. Furthermore, significantly less mucus glycoproteins were seen in the lungs of PNU-142731A-treated OA/OA mice. Reverse transcription-polymerase chain reaction of lung tissue from PNU-142731A-dosed OA/OA mice demonstrated that mRNA for Th2 cytokines was less than that in vehicle-treated OA/OA controls. OA-elicited production of IL-4 by disaggregated lung tissue cells from PNU-142371A-treated OA/OA mice was also less than that of controls. In contrast, the release of Th1 cytokines (IL-2 and interferon-γ) were elevated. Similarly, the OA-stimulated release of Th2 cytokines (IL-5 and IL-10) by splenocytes from PNU-142731A-treated OA/OA mice were inhibited. Combined therapy of OA/OA mice with PNU-142731A and suboptimal doses of dexamethasone revealed that PNU-142731A had steroid-sparing effects. These characteristics of PNU-142731A in a murine model of allergic tissue inflammation support its clinical development as a potential treatment for asthma.

Footnotes

  • Send reprint requests to: Jia En Chin, Ph.D., Pharmacology Department (7250–209-217), Pharmacia and Upjohn, Inc., 301 Henrietta St., Kalamazoo, MI 49001. E-mail: Jia.E.Chin{at}am.pnu.com

  • ↵1 Financial support for this work was provided by Pharmacia and Upjohn, Inc., Kalamazoo, Michigan. Part of this work was presented in abstract form at the American Thoracic Society, Chicago, Illinois, April 24–29, 1998 (Chin et al., 1998a).

  • Abbreviations:
    BAL
    bronchoalveolar lavage
    BALF
    bronchoalveolar lavage fluid
    FBS
    fetal bovine serum
    IFN
    interferon
    IL
    interleukin
    OA
    ovalbumin
    PAS
    periodic acid-Schiff
    • Received December 22, 1998.
    • Accepted March 24, 1999.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 290 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 290, Issue 1
1 Jul 1999
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Preclinical Evaluation of Anti-inflammatory Activities of the Novel Pyrrolopyrimidine PNU-142731A, a Potential Treatment for Asthma
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Preclinical Evaluation of Anti-inflammatory Activities of the Novel Pyrrolopyrimidine PNU-142731A, a Potential Treatment for Asthma

Jia En Chin, Cheryl A. Hatfield, Greg E. Winterrowd, Raymond F. Krzesicki, Kathy L. Shull, Stephen F. Fidler, Karen P. Kolbasa, John R. Brashler, Robert L. Griffin, William E. Fleming, James M. Justen, Lee S. Banitt, Gordon L. Bundy and Ivan M. Richards
Journal of Pharmacology and Experimental Therapeutics July 1, 1999, 290 (1) 188-195;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Preclinical Evaluation of Anti-inflammatory Activities of the Novel Pyrrolopyrimidine PNU-142731A, a Potential Treatment for Asthma

Jia En Chin, Cheryl A. Hatfield, Greg E. Winterrowd, Raymond F. Krzesicki, Kathy L. Shull, Stephen F. Fidler, Karen P. Kolbasa, John R. Brashler, Robert L. Griffin, William E. Fleming, James M. Justen, Lee S. Banitt, Gordon L. Bundy and Ivan M. Richards
Journal of Pharmacology and Experimental Therapeutics July 1, 1999, 290 (1) 188-195;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • CRV431 Decreases Liver Fibrosis and Tumor Development
  • Antinociceptive Properties of Fenfluramine, a Serotonin Reuptake Inhibitor, in a Rat Model of Neuropathy
  • Antagonism of Immunostimulatory CpG-Oligodeoxynucleotides by 4-Aminoquinolines and Other Weak Bases: Mechanistic Studies
Show more Article

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics